Speculation of AstraZeneca/Starpharma indication - Could it be AZD0466, page-10

AstraZeneca revenues decline but CEO praises pipeline progress



Pascal Soriot, AstraZeneca chief executive, said:

Our good start to the year supported our guidance for 2017. Notably, emerging markets became our largest region, representing 32 per cent of sales. The pipeline continued to deliver in what we expect will be a pivotal year for AstraZeneca as we announced important developments, in particular in oncology. The total revenue performance reflected the transitional impact of recent patent expiries, which is expected to recede in the second half of the year. Importantly, we anticipate the significant progress of the pipeline to continue, including our immuno-oncology and targeted treatments. We will also maintain our commitment to drive efficiency across the company to support our efforts to bring



https://www.ft.com/content/2e14ea43-4edf-36c1-be2a-fe56e5f23186